Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: “Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial”.
Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more